Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of EUR 487.44 million. The enterprise value is 433.76 million.
Market Cap | 487.44M |
Enterprise Value | 433.76M |
Important Dates
The last earnings date was Thursday, March 13, 2025.
Earnings Date | Mar 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 680.31 million shares outstanding. The number of shares has increased by 4.90% in one year.
Current Share Class | n/a |
Shares Outstanding | 680.31M |
Shares Change (YoY) | +4.90% |
Shares Change (QoQ) | +43.13% |
Owned by Insiders (%) | 3.21% |
Owned by Institutions (%) | 7.41% |
Float | 653.89M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.72 |
PB Ratio | 2.47 |
P/TBV Ratio | 3.14 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 78.91, with an EV/FCF ratio of -173.86.
EV / Earnings | -40.72 |
EV / Sales | 1.51 |
EV / EBITDA | 78.91 |
EV / EBIT | n/a |
EV / FCF | -173.86 |
Financial Position
The company has a current ratio of 3.78, with a Debt / Equity ratio of 0.51.
Current Ratio | 3.78 |
Quick Ratio | 3.02 |
Debt / Equity | 0.51 |
Debt / EBITDA | 15.08 |
Debt / FCF | -43.48 |
Interest Coverage | -0.87 |
Financial Efficiency
Return on equity (ROE) is -5.00% and return on invested capital (ROIC) is -1.49%.
Return on Equity (ROE) | -5.00% |
Return on Assets (ROA) | -1.25% |
Return on Invested Capital (ROIC) | -1.49% |
Return on Capital Employed (ROCE) | -2.64% |
Revenue Per Employee | 751,480 |
Profits Per Employee | -27,882 |
Employee Count | 382 |
Asset Turnover | 0.69 |
Inventory Turnover | 0.63 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.48% in the last 52 weeks. The beta is 0.64, so Pharming Group's price volatility has been lower than the market average.
Beta (5Y) | 0.64 |
52-Week Price Change | -27.48% |
50-Day Moving Average | 0.83 |
200-Day Moving Average | 0.78 |
Relative Strength Index (RSI) | 34.21 |
Average Volume (20 Days) | 8,871,705 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharming Group had revenue of EUR 287.07 million and -10.65 million in losses. Loss per share was -0.02.
Revenue | 287.07M |
Gross Profit | 252.87M |
Operating Income | -8.33M |
Pretax Income | -8.22M |
Net Income | -10.65M |
EBITDA | 7.19M |
EBIT | -8.33M |
Loss Per Share | -0.02 |
Balance Sheet
The company has 162.17 million in cash and 108.48 million in debt, giving a net cash position of 53.68 million or 0.08 per share.
Cash & Cash Equivalents | 162.17M |
Total Debt | 108.48M |
Net Cash | 53.68M |
Net Cash Per Share | 0.08 |
Equity (Book Value) | 214.30M |
Book Value Per Share | 0.29 |
Working Capital | 197.91M |
Cash Flow
In the last 12 months, operating cash flow was -1.73 million and capital expenditures -763,061, giving a free cash flow of -2.49 million.
Operating Cash Flow | -1.73M |
Capital Expenditures | -763,061 |
Free Cash Flow | -2.49M |
FCF Per Share | -0.00 |
Margins
Gross margin is 88.09%, with operating and profit margins of -2.90% and -3.71%.
Gross Margin | 88.09% |
Operating Margin | -2.90% |
Pretax Margin | -2.86% |
Profit Margin | -3.71% |
EBITDA Margin | 2.51% |
EBIT Margin | -2.90% |
FCF Margin | n/a |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -4.90% |
Shareholder Yield | -4.90% |
Earnings Yield | -2.19% |
FCF Yield | -0.51% |
Stock Splits
The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.
Last Split Date | Mar 5, 2013 |
Split Type | Reverse |
Split Ratio | 0.1 |
Scores
Pharming Group has an Altman Z-Score of 2.43. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.43 |
Piotroski F-Score | n/a |